quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·51d
PRRelease
Orchestra BioMed Holdings Inc. logo

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT

OBIO· Orchestra BioMed Holdings Inc.
Health Care
Original source

Companies

  • OBIO
    Orchestra BioMed Holdings Inc.
    Health Care

Recent analyst ratings

  • Dec 10UpdateTD Cowen$15.00
  • Aug 20UpdateBTIG Research-
  • Mar 20UpdateBTIG Research$12.00
  • Jan 2UpdateBarclays$16.00
  • Aug 22UpdateH.C. Wainwright$14.00
  • Jul 25UpdateB. Riley Securities$15.00

Related

  • PR20h
    Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
  • INSIDER27d
    SEC Form 4 filed by Sherman Darren
  • INSIDER27d
    SEC Form 4 filed by Aiello Joshua
  • INSIDER27d
    SEC Form 4 filed by Hochman David P
  • INSIDER38d
    Officer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)
  • PR43d
    Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
  • SEC43d
    SEC Form 10-K filed by Orchestra BioMed Holdings Inc.
  • SEC55d
    Amendment: SEC Form SCHEDULE 13G/A filed by Orchestra BioMed Holdings Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022